UA138743U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of genes of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of endothelin, C-terminal propeptide of collagen type I (SISR), interleukin 6, IL-6 ), homocysteine and homozygous carrier 677-TT, 786-CC and endothelin levels> 10 ng / ml, SISR <102 ng / ml, IL-6> 10 ng / l, PSA> 6 mg / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

Useful model The method of predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include radiography, examination of a biopsy of the synovial membrane, synovial fluid, a biopsy of cartilage (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - T. 2. - E. 186-196). The disadvantage of these methods is the lack of an opportunity to predict the dynamics of the process in the early subclinical stages, to prevent its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEV) is determined in the patient's blood serum

C677T), nitric oxide synthase (EMO5 T786C), content of endothelin, C-terminal propeptide of collagen

Type I (SISR), interleukin 6 (IL-6), C-reactive protein (CRP), homocysteine. With homozygous carriers of 677-TT, 786-SS, levels of endothelin 210 ng/ml, SISR "102 ng/ml, IL-6 510 ng/l, SRP "6 mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, X-rays are taken, the polymorphism of MTNEV C677T, emMO5 T786C genes, the content of endothelin, SISR, IL-6, SRP, and homocysteine are determined by the immunoenzymatic method. With homozygous carriers of 677-TT, 786-SS, levels of endothelin 210 ng/ml, SISR "102 ng/ml, IL-6 "10 ng/l, SRP "6 mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method

Patient M., 56 years old, was hospitalized for pain in the left knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. Polymorphisms of MTNEV C677T and emo5 17860 genes were determined in blood serum. The content of endothelin, SISR, IL-6, SRP, and homocysteine was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, endothelin levels - 24 ng/ml, SISR - 78 ng/ml, IL-6-25 ng/l, SRP -15 mg/l, homocysteine - 32 μmol/l. The development of osteoarthritis was diagnosed. After 13 months on

X-rays revealed the phenomena of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphisms of the methylenetetrahydrofolate reductase (MTNEV C677Т), nitric oxide synthase (ЕМО5 1786С), content of endothelin, C-terminal propeptide of type I collagen ( SISR), interleukin 6 (IL-6), C-reactive protein (SRP), homocysteine and with homozygous carriers of 677-TT, 786-SS and endothelin levels of 210 ng/ml, SISR "102 ng/ml, IL-6" 10 ng/l, SRP »6 mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.